CBST Financial Facts
Cost of product revenues: 94.96MInternational product revenues: 16.62M
See Full Income Statement
In-process research and development: 237.4M
Accumulated other comprehensive (loss) income: -1.77M
See Full Balance Sheet
Cubist Pharmaceuticals (CBST) Earnings
|
Expand Research on CBST
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +1,641.8% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +0.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
10/21/14  |
 |
Q314 | $0.58 | $0.04 | +$0.54 | $309.2M | $305.5M | = |  | | Details |
| 7/22/14 |
|
Q214 | $0.23 | $0.01 | +$0.22 | $294.4M | $299.6M | = | | | Details |
| 4/22/14 |
|
Q114 | $0.10 | N/A | N/A | $261.2M | $285.24M | = | | | Details |
| 1/23/14 |
|
Q413 | $0.29 | -$0.01 | +$0.30 | $299.7M | $285.47M | = | | | Details |
| 10/22/13 |
Q313 | $0.41 | $0.35 | +$0.06 | $266M | $267.96M | N/A | | | Details | |
| 7/18/13 |
|
Q213 | $0.42 | $0.38 | +$0.04 | $258.8M | $254.93M | N/A | | | Details |
| 4/18/13 |
|
Q113 | $0.34 | $0.31 | +$0.03 | $229.9M | $243.55M | N/A | | | Details |
| 1/23/13 |
|
Q412 | $0.48 | $0.48 | $0.00 | $245.9M | $246.42M | N/A | | | Details |
